checkAd

     141  0 Kommentare Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement - Seite 3

    Forward-Looking Statements

    This press release may contain forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including those relating to the timing and completion of the proposed offering and other statement that are predictive in nature. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release and other factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “risk factors” in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

    Investor Relations Contact:
    Torsten Hombeck, Ph.D.
    Chief Financial Officer
    Aspira Women’s Health
    investors@aspirawh.com 


    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement - Seite 3 AUSTIN, Texas, Jan. 25, 2024 (GLOBE NEWSWIRE) - Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced …

    Schreibe Deinen Kommentar

    Disclaimer